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EVIDENCE BASED MEDICINE
Benefit of neuroprotection in acute ischaemic stroke, shall we dare to hope?
Anjum Akhtar, Ayeesha Kamran Kamal
Calcium influx is the final pathway of death in hypoxia.
Numerous randomized clinical trials have been
conducted to assess the effect of calcium channel
blockade for neuroprotection in acute ischaemic stroke
but the majority of them failed to show any benefit.

What is the study under consideration?
"Ginsenoside-RD improves the outcome of acute
ischaemic stroke", is the randomized double blind
placebo-controlled multicenter trial by Liu et al which
described that Ginseniside-RD, a receptor operated
calcium channel antagonist that improved the functional
outcome in patients with acute ischaemic stroke.

What was the study design?
This study enrolled patients aged 18-75 years with the
clinical diagnosis of primary ischaemic stroke, who
presented within 72 hours after onset of the
symptoms. They selected the patients with NIHSS
score of 5-22 (moderate strokes). These patients
received the daily infusion of Ginesinoside-RD or
placebo for 14 days.

What was the outcome?
They noticed that Ginesinoside- RD markedly improved
the mRs at 3 months with no short term improvement of
neurological function in non-lacunar stroke. For lacunar
stroke they reported that the improvement of short term
neurological function determined by NIHSS score was
present on day 15.
Stroke Service and Vascular Fellowship Program, International Cerebrovascular
Translational Clinical Research Training Program (Fogarty International Center
and National Institute of Neurologic Disorders and Stroke), Aga Khan
University Hospital, Karachi, Pakistan.
Correspondence: Ayeesha Kamran Kamal. Email: ayeesha.kamal@aku.edu

What were the conclusions?
They concluded that Ginesinoside-RD has its early effect
on free radical scavenging pathway by protecting the
mitochondria, restoring the energy and inhibiting the
apoptosis. It has late anti-inflammatory effect as well. This
agent does not cause hypotension.

Why is this study important?
Of the 15 million stroke deaths, two thirds occur in
developing countries. We have only one option for the
reduction of disability from acute stroke in the form of tissue
plasminogen activator which has a very narrow window
period of 3 to 4.5 hours with risk of bleed as well. We need
safer agents with longer therapeutic windows to treat more
patients. Ginsenoside-RD has a long window period of 72
hours which will enable more patients to fall in this window.
It is interesting that this agent is showing neuroprotective
effects, since most trials have hitherto failed to do so. It does
raise the hope for neuroprotection in stroke.

Acknowledgement and Disclosure
Statement
The International Cerebrovascular Translational Clinical
Research and Training Program (ICT-CRT) at the Aga
Khan University is supported by funds from the Award
Number D43TW008660 from the Fogarty International
Center and the National Institute of Neurologic
Disorders and Stroke. The content is solely the
responsibility of the authors and does not necessarily
represent the official views of the Fogarty International
Center or the National Institutes of Health.

Recommended Reading
1.

Liu X, Wang L, Wen A, Yang J, Yan Y, Song Y, et al. Ginsenoside-Rd
improves outcome of acute ischaemic stroke - a randomized,
double-blind, placebo-controlled, multicenter trial. Eur J Neurol
Jun; 19: 855-63.

J Pak Med Assoc

